Document Detail

Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
MedLine Citation:
PMID:  15598674     Owner:  NLM     Status:  MEDLINE    
Severe insulin resistance is a key abnormality in obese women with polycystic ovary syndrome (PCOS). The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment. Fifty-two women with PCOS were randomly allocated to receive either pioglitazone (30 mg/d, n = 25) or metformin (850 mg three times daily, n = 27) and were assessed before and after 6 months. Body weight, body mass index, and waist to hip ratio increased significantly (P </= 0.05) after pioglitazone treatment but not after metformin treatment. Fasting serum insulin concentration (P < 0.001 for both drugs) and the area under the insulin curve during a 2-h oral glucose tolerance test decreased after pioglitazone (P < 0.002) or metformin (P < 0.05) treatment. IR (homeostasis model of assessment-IR index) decreased and insulin sensitivity (elevation of the quantitative insulin sensitivity check index and the fasting glucose to insulin ratio) increased (P </= 0.008) after treatment with either drug. Hirsutism (P < 0.05) and serum concentrations of free testosterone (P < 0.02) and androstenedione (P < 0.01) declined to a similar extent after treatment with the drugs. Treatment with pioglitazone or metformin was associated with the occurrence of pregnancy (n = 5 and n = 3, respectively). These results suggest that pioglitazone is as effective as metformin in improving insulin sensitivity and hyperandrogenism, despite an increase in body weight, body mass index, and the waist to hip ratio associated with pioglitazone.
C Ortega-González; S Luna; L Hernández; G Crespo; P Aguayo; G Arteaga-Troncoso; A Parra
Related Documents :
18687824 - Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 ...
14642684 - The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonis...
19237574 - Antidiabetic drug metformin (glucophager) increases biogenesis of alzheimer's amyloid p...
20129254 - Pharmacologic management of the older patient with type 2 diabetes mellitus.
21995824 - Extracellular signal-regulated kinase (erk) inhibition decreases arginase activity and ...
21219424 - Alcohol consumption and other psycho-social conditions as important factors in the deve...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial     Date:  2004-12-14
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  90     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-03-10     Completed Date:  2005-04-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1360-5     Citation Subset:  AIM; IM    
Instituto Nacional de Perinatología, Department of Endocrinology, Montes Urales 800, Lomas Virreyes, 11000 México City, México.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Androgens / blood
Blood Glucose
Hyperandrogenism / drug therapy*
Hypoglycemic Agents / administration & dosage*
Insulin Resistance*
Metformin / administration & dosage*
Obesity / drug therapy,  metabolism
Polycystic Ovary Syndrome / drug therapy*,  metabolism
Pregnancy Outcome
Thiazolidinediones / administration & dosage*
Treatment Outcome
Reg. No./Substance:
0/Androgens; 0/Blood Glucose; 0/Hypoglycemic Agents; 0/Thiazolidinediones; 111025-46-8/pioglitazone; 657-24-9/Metformin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reevaluation of amino acid stimulation of protein synthesis in murine- and human-derived skeletal mu...
Next Document:  Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetat...